Phase 1 Study of a Long-acting Injectable S-892216 in Healthy Adult Participants
Shionogi
Summary
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.
Eligibility
- Age range
- 18–55 years
- Sex
- Male
- Healthy volunteers
- Yes
Key Inclusion Criteria: * Body mass index (BMI) ≥18.5 and ≤32.0 kilograms (kg)/square meter (m\^2) Key Exclusion Criteria: * Presence or history of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, neurological, or ophthalmological (for example, increased intra-ocular pressure) disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data per the investigator's assessment. * History of cancer except for basal…
Interventions
- DrugS-892216-LAI
S-892216-LAI injection will be administered per schedule specified in the arm description.
- DrugPlacebo
Physiological saline will be administered per schedule specified in the arm description.
Locations (2)
- ICON Clinical Research: LenexaLenexa, Kansas
- ICON Clinical Research: Salt Lake CitySalt Lake City, Utah